Skip to content

Annexon ANNX Financing Cash Flow

Financing Cash Flow at other companies

Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
-$802.2M+26.3%
Dianthus Therapeutics logo
Dianthus TherapeuticsDNTH
$739.41M+459,161%
Omeros logo
OmerosOMER
-$21.98M-1,095%
Vor Biopharma logo
Vor BiopharmaVOR
$74.87M+12,455%
Cullinan Therapeutics, Inc. logo
Cullinan Therapeutics, Inc.CGEM
$380K
Nektar Therapeutics logo
Nektar TherapeuticsNKTR
$529.55M+7,564,886%

Other financials

Income statement

See full
Operating income-$46.1M+19.8%
Net income-$44.1M+18.8%
EPS (diluted)-$0.23+37.8%

Balance sheet

See full
Cash & equivalents$175.2M+80.4%
Total debt$25.4M-10.2%
Total equity$204.5M-16.1%
Total assets$262.9M-13.2%

Cash flow

See full
Operating cash flow-$46.8M+6.5%
CapEx--100%
Free cash flow-$46.8M+6.6%

Valuation

See full
Market cap$868.37M+233%
Enterprise value$718.59M+274%

Returns & leverage

See full
Return on equity-87.6%+42.3pp
Debt / equity0.1×0.0×
Current ratio6.4×-1.6×

Where this comes from

Reported directly by Annexon in its filing.

Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInFinancingActivities.

The official record: Annexon’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Annexon's financing cash flow.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Annexon's financing cash flow?
Annexon (ANNX) reported financing cash flow of $32.9M in Q1 2026.
How has Annexon's financing cash flow changed year-over-year?
Annexon's financing cash flow increased by 55655.9% year-over-year, from $59K to $32.9M.
What is the long-term trend for Annexon's financing cash flow?
Over 4 years (2021 to 2025), Annexon's financing cash flow has grown at a 176.3% compound annual growth rate (CAGR), from $1.87M to $108.86M.
What does financing cash flow mean?
Total net cash provided by or used in financing activities — debt issuance/repayment, equity transactions, and dividend payments.